Vaccitech接受HBV002的第一例患者治疗，这是针对慢性HBV患者的VT

StephenW

Vaccitech Doses First Patient in HBV002, a Phase 1b/2a Clinical Trial of VTP-300 Immunotherapeutic Candidate for Chronic HBV Patients
Email Print Friendly Share
February 01, 2021 03:00 ET | Source: Vaccitech Limited

OXFORD, United Kingdom, Feb. 01, 2021 (GLOBE NEWSWIRE) -- Vaccitech Ltd, a clinical-stage biopharmaceutical company engaged in the discovery and development of novel immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancer, today announced the dosing of the first patient in HBV002. HBV002 is a Phase 1b/2a clinical trial designed to evaluate the safety and preliminary efficacy of VTP-300 both with and without a low-dose anti-PD-1 antibody in patients with chronic hepatitis B (CHB) infection. The study plans to enroll 64 patients in South Korea, Taiwan and the UK.

VTP-300 will utilize Vaccitech’s ChAdOx1-MVA prime-boost combination to elicit an immune response against HBV. The HBV DNA sequence contained in the viral vectors is derived from a genotype C sequence, which is the most common genotype circulating worldwide. The platform has demonstrated robust activation of cytotoxic CD8+ T cells (immune cells associated with clearance of HBV infected cells), which are believed to have the potential to lead to a functional cure in combination with current anti-viral therapy and a low-dose checkpoint inhibitor.

“HBV infection is a serious chronic viral infection of the liver that affects an estimated 257 million people worldwide, including more than two million in the U.S. and 13 million in Europe, and results in approximately 880 thousand deaths per year,” said Bill Enright, Chief Executive Officer of Vaccitech. “Prophylactic vaccines cannot treat HBV infection, and there are no highly effective curative regimens. VTP-300, which we designed as a potential functional cure of chronic HBV, represents an opportunity to address this serious unmet need. We are looking forward to the results of this trial, and if successful, advancing VTP-300 into later clinical development.”

Prof Ellie Barnes, from University of Oxford, and Chief Investigator on the HBV002 trial says, “By targeting the HBV genotype C, which is the most prevalent worldwide and is particularly common where the virus is endemic, we have designed an immunotherapeutic to address a very broad population of patients. We also believe it may induce T cell responses against other common genotypes, and given the promising preclinical results, we are very excited to see the first patient treated in this latest clinical trial.”

Notes to editors:

About Vaccitech Ltd.

Vaccitech is a clinical stage T cell immunotherapy and vaccine company developing products to treat infectious diseases and cancer. The company’s proprietary platform, comprising Chimpanzee Adenovirus (prime) and MVA (boost) is designed to induce, boost and maintain CD8+ and CD4+ T cells, as well as antibodies. The Vaccitech prime-boost platform is licensed from one of the most prestigious vaccine research institutes in the world, the Jenner Institute at the University of Oxford. In partnership with the Jenner, Vaccitech co-invented and led aspects of the early development of a SARS-CoV-2 (COVID-19) vaccine, based upon its proprietary Chimpanzee Adenovirus Oxford, or ChAdOx1, platform. The COVID-19 vaccine, now known as AZD1222, was assigned by Vaccitech to Oxford University Innovation and has been licensed by Oxford University Innovation to AstraZeneca, which has received emergency use authorization in countries across the world.

Vaccitech has multiple therapeutic programs in the clinic including a Phase 1/2 program for chronic HBV and HPV, a Phase 2 program for prostate cancer, as well as a program preparing to enter the clinic for NSCLC. The company is also co-developing prophylactic products for MERS coronavirus and Herpes Zoster with international collaborators. Vaccitech is backed by leading institutions including GV, Sequoia Capital China, Korea Investment Partners and Oxford Sciences Innovation.

Media contacts:

Katja Stout, Scius Communications (EU)
Direct: +44 (0) 7789435990
Email: [email protected]

Ryo Imai / Robert Flamm, Ph.D. (U.S.)
Burns McClellan, Inc.
212-213-0006 ext. 315 / 364
[email protected] / [email protected]

Henry Hodge, Vaccitech
Direct: +44 (0) 7533 421 442
Email: [email protected]

StephenW

Vaccitech接受HBV002的第一例患者治疗，这是针对慢性HBV患者的VTP-300免疫治疗候选药物1b / 2a期临床试验
电子邮件打印友好分享
美国东部时间2021年2月1日03:00 |资料来源：Vaccitech Limited

2021年2月1日，英国牛津（全球新闻）-Vaccitech Ltd是一家临床阶段的生物制药公司，致力于发现和开发用于治疗和预防传染病和癌症的新型免疫疗法和疫苗，今天宣布HBV002中第一位患者的剂量。 HBV002是一项1b / 2a期临床试验，旨在评估带有或不带有低剂量抗PD-1抗体的VTP-300在慢性乙型肝炎（CHB）感染患者中的安全性和初步疗效。该研究计划在韩国，台湾和英国招募64名患者。

VTP-300将利用Vaccitech的ChAdOx1-MVA初免-增强组合引发针对HBV的免疫反应。病毒载体中包含的HBV DNA序列源自基因型C序列，后者是世界范围内最常见的基因型。该平台已证明细胞毒性CD8 + T细胞（与清除HBV感染的细胞有关的免疫细胞）具有强大的活化作用，据信与当前的抗病毒治疗和低剂量检查点结合使用，有可能导致功能性治愈抑制剂。

Bill Enright说：“ HBV感染是肝脏的一种严重的慢性病毒感染，影响全世界约2.57亿人，其中包括美国的200万人和欧洲的1300万人，每年导致约88万人死亡。” Vaccitech首席执行官。预防性疫苗不能治疗HBV感染，也没有高效的治疗方案。我们将VTP-300设计为慢性HBV的潜在功能疗法，它为解决这一严重的未满足需求提供了机会。我们期待该试验的结果，如果成功的话，也将VTP-300推进以后的临床开发。”

牛津大学的Ellie Barnes教授兼HBV002试验的首席研究员说：“通过针对C型HBV基因型（在世界范围内最普遍，在该病毒为地方性流行特别常见），我们设计了一种免疫疗法来解决非常广泛的患者群体。我们也相信它可能诱导针对其他常见基因型的T细胞反应，并且鉴于有希望的临床前结果，我们很高兴看到这一最新临床试验中的首位患者接受了治疗。”

编者注：

关于Vaccitech Ltd.

Vaccitech是一家临床T细胞免疫疗法和疫苗公司，致力于开发治​​疗传染病和癌症的产品。该公司的专有平台包括黑猩猩腺病毒（prime）和MVA（boost），旨在诱导，增强和维持CD8 +和CD4 + T细胞以及抗体。 Vaccitech初免增压平台已获得世界上最负盛名的疫苗研究机构之一，即牛津大学詹纳研究所的许可。 Vaccitech与詹纳（Jenner）合作，共同开发并领导了基于其专有的黑猩猩腺病毒牛津牛津（ChAdOx1）平台的SARS-CoV-2（COVID-19）疫苗的早期开发。 Vaccitech将COVID-19疫苗（现称为AZD1222）分配给牛津大学创新公司，并已被牛津大学创新公司授权给阿斯利康，阿斯利康已在世界各地的国家获得了紧急使用授权。

Vaccitech在诊所中有多个治疗计划，包括针对慢性HBV和HPV的1/2期计划，针对前列腺癌的2期计划，以及准备进入NSCLC的计划。该公司还与国际合作伙伴共同开发针对MERS冠状病毒和带状疱疹的预防产品。 Vaccitech得到GV，红杉资本中国，韩国投资伙伴和牛津科学创新等领先机构的支持。

媒体联系人：

Scius Communications（EU）的Katja Stout
直接电话：+44（0）7789435990
电子邮件：[email protected]

今井亮（Ryo Imai）/罗伯特·弗拉姆（Robert Flamm）博士（我们。）
Burns McClellan，Inc.
212-213-0006分机315/364
[email protected] / [email protected]

Vaccitech的Henry Hodge
直接：+44（0）7533421442
电子邮件：[email protected]